General Information of the Protein
Protein ID |
PT01206
|
||||
---|---|---|---|---|---|
Protein Name |
Histamine H1 receptor
|
||||
Gene Name |
HRH1
|
||||
Sequence |
MSLPNSSCLLEDKMCEGNKTTMASPQLMPLVVVLSTICLVTVGLNLLVLYAVRSERKLHTVGNLYIVSLSVADLIVGAVVMPMNILYLLMSKWSLGRPLCLFWLSMDYVASTASIFSVFILCIDRYRSVQQPLRYLKYRTKTRASATILGAWFLSFLWVIPILGWNHFMQQTSVRREDKCETDFYDVTWFKVMTAIINFYLPTLLMLWFYAKIYKAVRQHCQHRELINRSLPSFSEIKLRPENPKGDAKKPGKESPWEVLKRKPKDAGGGSVLKSPSQTPKEMKSPVVFSQEDDREVDKLYCFPLDIVHMQAAAEGSSRDYVAVNRSHGQLKTDEQGLNTHGASEISEDQMLGDSQSFSRTDSDTTTETAPGKGKLRSGSNTGLDYIKFTWKRLRSHSRQYVSGLHMNRERKAAKQLGFIMAAFILCWIPYFIFFMVIAFCKNCCNEHLHMFTIWLGYINSTLNPLIYPLCNENFKKTFKRILHIRS
Show/Hide
|
||||
Organism |
Homo sapiens, Human
|
||||
Protein Classification |
Membrane receptor
>
Family A G protein-coupled receptor
>
Small molecule receptor (family A GPCR)
>
Monoamine receptor
>
Histamine receptor
|
||||
Function |
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Show/Hide
|
||||
Uniprot ID |
Show/Hide
|
||||
Ensembl ID | |||||
HGNC ID | |||||
Subcellular Location |
Cell membrane
|
Map of Molecular Bioactivity Related to the Protein
Map of Molecular Bioactivity Related to the Protein Protein Cell Line Compound Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
---|
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000901 , 661W
Cell Line ID: CL000011 , CHO
Cell Line ID: CL000026 , CHO-K1
Cell Line ID: CL000053 , COS-7
Cell Line ID: CL000386 , Flp-In-CHO
Cell Line ID: CL000025 , HEK-293T
Cell Line ID: CL000006 , HEK293
Cell Line ID: CL000065 , HEK293-EBNA
Cell Line ID: CL000017 , HeLa
Cell Line ID: CL000035 , NIH 3T3
Cell Line ID: CL000013 , Sf9
Cell Line ID: CL000074 , SK-N-MC
Cell Line ID: CL000289 , SK-N-SH
Biochemical Assays
Clinical Information about the Protein
Target 1 ( Histamine H1 receptor (H1R) )
Target Type | Successful Target | ||||
---|---|---|---|---|---|
Disease | 20 Target-related Diseases | 20 | |||
1 | Allergic rhinitis [ICD-11: CA08.0] | ||||
2 | Nasal congestion [ICD-11: MD11.9] | ||||
3 | Allergic conjunctivitis [ICD-11: 9A60.02] | ||||
4 | Hay fever [ICD-11: CA08.00] | ||||
5 | Vasomotor/allergic rhinitis [ICD-11: CA08] | ||||
6 | Vertigo meniere disease [ICD-11: AB31.0] | ||||
7 | Nausea [ICD-11: MD90] | ||||
8 | Rhinitis [ICD-11: FA20] | ||||
9 | Respiratory allergy [ICD-11: 4A80] | ||||
10 | Meniere disease [ICD-11: AB31.0] | ||||
11 | Depression [ICD-11: 6A70-6A7Z] | ||||
12 | Morning sickness [ICD-11: SC00] | ||||
13 | Parkinson disease [ICD-11: 8A00.0] | ||||
14 | Anxiety disorder [ICD-11: 6B00-6B0Z] | ||||
15 | Allergy [ICD-11: 4A80-4A85] | ||||
16 | Headache [ICD-11: 8A80-8A84] | ||||
17 | Common cold [ICD-11: CA00] | ||||
18 | Ocular allergy [ICD-11: 4A81] | ||||
19 | Hypersensitivity [ICD-11: 4A80-4A85] | ||||
20 | Allergic skin disorder [ICD-11: 4A82] | ||||
Approved Drug(s) | 45 Approved Drugs | 45 | |||
1 | Acrivastine | Approved | |||
2 | Antazoline | Approved | |||
3 | Azatadine | Approved | |||
4 | Azelastine | Approved | |||
5 | Bromodiphenhydramine | Approved | |||
6 | Brompheniramine | Approved | |||
7 | Carbinoxamine | Approved | |||
8 | Cetirizine | Approved | |||
9 | Chlorpheniramine | Approved | |||
10 | Cinnarizine | Approved | |||
11 | Clemastine | Approved | |||
12 | Cyclizine | Approved | |||
13 | Cyproheptadine | Approved | |||
14 | Desloratadine | Approved | |||
15 | Dexchlorpheniramine Maleate | Approved | |||
16 | Dimenhydrinate | Approved | |||
17 | Dimethindene | Approved | |||
18 | Diphenhydramine | Approved | |||
19 | Diphenylpyraline | Approved | |||
20 | Doxepin | Approved | |||
21 | Doxylamine | Approved | |||
22 | Emedastine | Approved | |||
23 | Epinastine | Approved | |||
24 | Ergotidine | Approved | |||
25 | Ethopropazine | Approved | |||
26 | Fexofenadine | Approved | |||
27 | Hydroxyzine | Approved | |||
28 | Ketotifen | Approved | |||
29 | Levocetirizine dihydrochloride | Approved | |||
30 | Loratadine | Approved | |||
31 | Mepyramine | Approved | |||
32 | Mepyramine maleate | Approved | |||
33 | Mequitazine | Approved | |||
34 | Methdilazine | Approved | |||
35 | Mizolastine | Approved | |||
36 | Olopatadine | Approved | |||
37 | Oxatomide | Approved | |||
38 | Pemirolast | Approved | |||
39 | Phenindamine | Approved | |||
40 | Pheniramine | Approved | |||
41 | Promethazine | Approved | |||
42 | Tranilast | Approved | |||
43 | Trimeprazine | Approved | |||
44 | Tripelennamine | Approved | |||
45 | Triprolidine | Approved | |||
Clinical Trial Drug(s) | 1 Clinical Trial Drug | 1 | |||
1 | Vapitadine | Phase 2 | |||
Discontinued Drug(s) | 3 Discontinued Drugs | 3 | |||
1 | Astemizole | Withdrawn from market | |||
2 | Terfenadine | Withdrawn from market | |||
3 | GSK1004723 | Discontinued in Phase 1 |